DNA2.0 enters into strategic alliance with Aldevron
Under the agreement, DNA2.0 will use its GeneGPS technology and Aldevron will use its protein production experience for improving recombinant protein production in insect cell culture. Insect cell
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).